Johnson & Johnson: New data from J&J's bladder cancer drug-device trial strengthens support for NDA
J&J submitted a New Drug Application to the FDA for TAR-200 in January 2025 following positive data from the SunRISe-1 trial. The post New data from J&J's bladder cancer drug-device trial strengthens support for NDA appeared first on Medical Device Network.
Read full article »
Johnson & Johnson is a New Jersey-based firm that engages in research, manufacturing and sale of healthcare products including consumer, pharmaceutical and medical devices.
Read more